Roche’s Itovebi Scores OS Goal In Breast Cancer

Just a few months after bagging US approval based on impressive progression-free survival data for its PI3K inhibitor, the Basel-headquartered giant is trumpeting a significant overall survival benefit for a drug that is expected to reinvigorate its breast cancer franchise.